Prepandemic influenza vaccine (H5N1) (surface antigen, inactivated, adjuvanted) Novartis Vaccines and Diagnostics यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

prepandemic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted) novartis vaccines and diagnostics

novartis vaccines and diagnostics s.r.l. - antigeni virusa influence (hemaglutinin i neuraminidaza) soja a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - cjepiva - aktivna imunizacija protiv h5n1 podtipa virusa gripe a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

COVID-19 Vaccine (inactivated, adjuvanted) Valneva यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

covid-19 vaccine (inactivated, adjuvanted) valneva

valneva austria gmbh - covid-19 vaccine (inactivated, adjuvanted, adsorbed) - covid-19 virus infection - cjepiva - covid-19 vaccine (inactivated, adjuvanted) valneva is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 to 50 years of age.  the use of this vaccine should be in accordance with official recommendations.

Zoonotic Influenza Vaccine Seqirus यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

zoonotic influenza vaccine seqirus

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - cjepiva - active immunisation against h5 subtype of influenza a virus.

ORALNA BIVALENTNA TIP 1 i 3 POLIOMIJELITIS VAKCINA (▼) ≥ 6 Log10Dozna forma/0.1 mL+ ≥ 5.8 Log10Dozna forma/0.1 mL oralna suspenz बोस्निया और हर्ज़ेगोविना - क्रोएशियाई - Agencija za lijekove i medicinska sredstva Bosne i Hercegovine (Агенција за лијекове и медицинска средства Босне и Херцеговине)

oralna bivalentna tip 1 i 3 poliomijelitis vakcina (▼) ≥ 6 log10dozna forma/0.1 ml+ ≥ 5.8 log10dozna forma/0.1 ml oralna suspenz

sanofi d.o.o. - oralna пропорциональному protiv poliomijelitisa, bivalentna, ziva atenuisana - oralna suspenzija - ≥ 6 log10dozna forma/0.1 ml+ ≥ 5.8 log10dozna forma/0.1 ml - svaka doza od 0,1 ml (dvije kapi) oralne suspenzije sadrži: virus poliomijelitisa tip 1*, ls c 2ab soj (živi oslabljeni), najmanje 6.0 log† ccid50 ‡ virus poliomijelitisa tip 3*, leon, soj 12a 1b (živi oslabljeni), najmanje 5.8 log† ccid50 ‡ *proizvedeno u vero celijama † prethodno izraženo kao minimalno 10 x ccid50 ‡ccid50:50% ćelija kultivirane infektivne doze (jedinica virusne infekcije)

Jcovden (previously COVID-19 Vaccine Janssen) यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

jcovden (previously covid-19 vaccine janssen)

janssen-cilag international nv - adenovirus type 26 encoding the sars-cov-2 spike glycoprotein (ad26.cov2-s) - covid-19 virus infection - cjepiva - jcovden is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 18 years of age and older. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Spikevax (previously COVID-19 Vaccine Moderna) यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

spikevax (previously covid-19 vaccine moderna)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - cjepiva - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

Menveo यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

menveo

gsk vaccines s.r.l. - meningokokna skupina a, c, w-135 i y konjugirano cjepivo - immunization; meningitis, meningococcal - bakterijska vakcina - vialsmenveo prikazana za aktivne imunizacije djece (od dvije godine), mladež i odrasle osobe sklone utjecaja na менингококк grupe a, c, w135 i y kako bi se spriječilo bolesti инвазионные. korištenje ovog cjepiva mora se provoditi u skladu sa službenim preporukama.

Focetria यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

focetria

novartis vaccines and diagnostics s.r.l. - influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/california/7/2009 (h1n1)-derived strain used nymc x-181 - influenza, human; immunization; disease outbreaks - cjepiva protiv gripe - profilakcija influence uzrokovana virusom a (h1n1v) 2009. focetria mora se koristiti u skladu sa službenim vodstvom.

Adjupanrix (previously Pandemic influenza vaccine (H5N1) (split virion, inactivated, adjuvanted) GlaxoSmithKline Biologicals) यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

adjupanrix (previously pandemic influenza vaccine (h5n1) (split virion, inactivated, adjuvanted) glaxosmithkline biologicals)

glaxosmithkline biologicals s.a. - split virusa influence, inaktiviran, koji sadrži antigen: a / vietnam / 1194/2004 (h5n1) kao soj koji se koristio (nibrg-14) - influenza, human; immunization; disease outbreaks - cjepiva - profilakcija gripe u službeno prijavljenoj pandemijskoj situaciji. cjepivo protiv influence pandemije treba koristiti u skladu s službenim smjernicama.

Pandemic influenza vaccine H5N1 AstraZeneca (previously Pandemic influenza vaccine H5N1 Medimmune) यूरोपीय संघ - क्रोएशियाई - EMA (European Medicines Agency)

pandemic influenza vaccine h5n1 astrazeneca (previously pandemic influenza vaccine h5n1 medimmune)

astrazeneca ab - reassortant virus gripe (uživo oslabljenim) sljedeće soja: soja a/vijetnam/1203/2004 (h5n1) - gripa, ljudska - cjepiva - profilaksa influence u službeno deklariranoj pandemijskoj situaciji kod djece i adolescenata od 12 mjeseci do 18 godina starosti. cjepivo protiv pandemijskog gripa h5n1 АстраЗенека mora se koristiti u skladu sa službenim vodstvom.